We recently published a list of These 10 Firms Took A Hit on Friday. In this article, we are going to take a look at where ...
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...
The Baltimore City Board of School Commissioners is suing Eli Lilly and Co., UnitedHealth Group, CVS and several other drug ...
Testing has shown reduced bioavailability due to impurities and fibril formation, rendering these products less effective ...
Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...
The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction ...
In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price ...
Novo Nordisk's financial strength is evident through its 74% historical average ROIC and 85% gross margin. See why I rate NVO ...
Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...
UBS analyst Jo Walton maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK750.00. The company’s ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback